Kairos Pharma Advances Cancer Research with Department of Defense Grant

Kairos Pharma Ltd. has received a Department of Defense grant to advance its critical research in lung cancer biomarkers, underscoring the company's commitment to developing innovative cancer therapeutics. The grant supports the company's ongoing efforts to understand and overcome drug resistance mechanisms in cancer treatment.

The company's lead candidate, ENV105, represents a significant breakthrough in cancer research. By targeting CD105, a protein identified as a key driver of treatment resistance, ENV105 aims to restore the effectiveness of standard cancer therapies across multiple cancer types. This approach could potentially transform how oncologists address treatment-resistant cancers, particularly in lung and prostate cancer patients.

Currently, Kairos is conducting two pivotal clinical trials: a Phase 2 trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer. The company expects to release safety and interim efficacy results in the second quarter of 2025, which could provide critical insights into the potential of their therapeutic approach.

In addition to ENV105, Kairos is developing KROS101, an immune response modulator that has already generated significant interest in the oncology research community. Recent presentations at key oncology conferences have highlighted the potential of this innovative therapeutic candidate.

The non-dilutive government grant, combined with expanding clinical trial networks and growing analyst coverage from firms like EF Hutton and HC Wainwright, positions Kairos Pharma as a potentially transformative player in cancer therapeutics. The company's robust intellectual property portfolio, which extends into the 2030s, suggests a long-term strategy for continued innovation in oncology treatment.

The research could have profound implications for cancer patients, particularly those experiencing drug resistance—a significant challenge in current cancer treatment protocols. By targeting the mechanisms that lead to treatment failure, Kairos Pharma's approach offers hope for more effective, personalized cancer therapies.